Background. 131 I-Metaiodobenzylguanidine ( 131 I-MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and 131 I-MIBG is concentrated in the liver after 131 I-MIBG therapy. The aim of our study was to analyze the effects of 131 I-MIBG therapy on thyroid and liver function. Procedure. Pre-and post-therapy thyroid and liver functions were reviewed in a total of 194 neuroblastoma patients treated with 131 I-MIBG therapy. The cumulative incidence over time was estimated for both thyroid and liver toxicities. The relationship to cumulative dose/kg, number of treatments, time from treatment to follow-up, sex, and patient age was examined. Results. In patients who presented with Grade 0 or 1 thyroid toxicity at baseline, 12 ± 4% experienced onset of or worsening to Grade 2 hypothyroidism and one patient developed Grade 2 hyperthyroidism by 2 years after 131 I-MIBG therapy. At 2 years post-131 I-MIBG therapy, 76 ± 4% patients experienced onset or worsening of hepatic toxicity to any grade, and 23 ± 5% experienced onset of or worsening to Grade 3 or 4 liver toxicity. Liver toxicity was usually transient asymptomatic transaminase elevation, frequently confounded by disease progression and other therapies. Conclusion. The prophylactic regimen of potassium iodide and potassium perchlorate with 131 I-MIBG therapy resulted in a low rate of significant hypothyroidism. Liver abnormalities following 131 I-MIBG therapy were primarily reversible and did not result in late toxicity. 131 I-MIBG therapy is a promising treatment for children with relapsed neuroblastoma with a relatively low rate of symptomatic thyroid or hepatic dysfunction.
INTRODUCTION
Neuroblastoma, the most common extra-cranial solid tumor in children, is an embryonal tumor derived from the peripheral sympathetic nervous system. It is highly malignant, with metastatic disease at diagnosis in half of cases. Despite improvement in outcome with intensification therapy and treatment of minimal residual disease, 15% of patients have disease that is refractory to induction chemotherapy, and more than 50% of patients who achieve initial remission ultimately relapse and die as a result of their disease [1] .
Metaiodobenzylguanidine (MIBG) is a guanethidine derivative and analogue of norepinephrine with specific affinity for neural crest tissues. When labeled with iodine-131 ( 131 I-MIBG), MIBG has shown activity against neuroblastoma, with response rates for refractory disease varying from 20% to 37% [2] [3] [4] [5] [6] [7] [8] [9] [10] . In a Phase II clinical trial of 164 patients, the response rate (complete and partial) for all patients was 36% [2] . While 131 I-MIBG has typically been used as a single agent in relapsed disease, several groups have increasingly used 131 I-MIBG alone earlier in the course of disease or combined with chemotherapy [11] [12] [13] [14] [15] [16] . With this expanding role, an understanding of the late toxicity of 131 I-MIBG has become increasingly important.
The most common toxicities associated with high-dose 131 I-MIBG targeted radiotherapy are primarily hematologic, with almost all patients requiring at least one platelet or red cell transfusion and with most patients developing neutropenia. Approximately 36% of patients also require autologous hematopoietic stem-cell rescue (ASCR) after 131 I-MIBG treatment [17] . The chief nonhematological toxicities reported with 131 I-MIBG therapy include transient nausea and vomiting, sialoadenitis, transient hepatic abnormalities, later adrenal insufficiency (<1%), and variable rates of hypothyroidism [18] [19] [20] [21] [22] [23] [24] . Secondary malignancies such as acute myelogenous leukemia and myelodysplastic syndrome have also been reported in 3-5% of children who have received 131 I-MIBG therapy to treat relapsed or refractory neuroblastoma [2, 25, 26] .
Thyroid function and liver function after 131 I-MIBG therapy are of particular interest because the radioactivity is often concentrated in these organs. Both the thyroid and the liver can be visualized on the 96 hr post infusion 131 I-MIBG scan after 131 I-MIBG therapy and the dissociated anion may be specifically concentrated in the thyroid. However, limited data are available to assess the acute and late effects of 131 I-MIBG therapy on thyroid and liver function. Reports of hypothyroidism following 131 I-MIBG therapy have been highly variable, with incidence rates ranging from 15% to 64% of patients. There has also been little systematic examination and no reports of late liver dysfunction associated with 131 I-MIBG therapy [19] [20] [21] [22] [23] .
We report here an analysis of thyroid and liver function for neuroblastoma patients with follow-up data after receiving therapy with 131 I-MIBG. We examined the relationship between liver and thyroid toxicity incidence and cumulative 131 I-MIBG dose/kg, number of treatments, sex, and patient age at the time of therapy. We also analyzed the relation of thyroid dysfunction with thyroid visualization on post-therapy 96 hr scans.
METHODS

Study Subjects
All evaluated patients either failed to achieve partial or complete response with standard induction therapy or developed progressive disease at any time prior to 131 I-MIBG therapy. All patients had demonstrated 131 I-MIBG uptake in skeletal or soft tissue prior to treatment. The vast majority of patients were heavily pre-treated, with a median of three prior regimens, and almost all had prior radiation therapy and surgery. All patients had total bilirubin ≤2× normal for age and aspartate transaminase (AST) and alanine transaminase (ALT) <5× normal for age. All patients were fully recovered from the toxic effects of prior therapy.
Eligibility for inclusion in this analysis included evaluation of baseline thyroid and liver function and at least one post-therapy value for thyroid function tests (thyroid stimulating hormone (TSH), free T4, or T4) and/or liver function tests (AST, ALT, total bilirubin). Patients were enrolled on therapeutic trials with 131 I-MIBG, and appropriate informed consent was obtained for all patients with approval by the institutional human research review board and radiation safety committee at treating institutions.
Treatment
Patients were treated between August 30, 1996 Patients were treated with 1-3 therapeutic doses of 131 I-MIBG, given intravenously over 1-2 hr with hydration and a Foley catheter for bladder protection. All patients remained in radiation-protected isolation for 2-7 days until radiation emissions met institutional regulations. The dose of radiation to the whole body from 131 I-MIBG was calculated for every patient using multiple measurements from a hand-held or ceiling-mounted Geiger counter [28] .
Thyroid Protection
To protect the thyroid from any dissociated 131-iodide from the therapeutic doses of 131 I-MIBG, patients were given an oral loading dose of 6 mg/kg of KI solution 8-12 hr prior to 131 I-MIBG infusion, then 1 mg/kg every 4 hr on days 0-6, and 1 mg/kg/day through day 45 post-infusion. Potassium perchlorate was also given as an additional oral blocking agent for 5 days post-infusion with a loading dose of 8 mg/kg, then 2 mg/kg every 6 hr on days 0-4, beginning 4 hr after the start of 131 I-MIBG infusion.
Monitoring
Patients on all studies were monitored weekly for a minimum of 6 weeks or until recovery from toxicity. Tumor response evaluations and hematologic, hepatic, renal, and endocrine toxicity evaluations were required at 3-month intervals for 1 year, then every 6 months, or until the patient died or went on to other therapy. Baseline abnormalities were noted if available.
Scan Review
A post-infusion 131 I-MIBG scan (median time of 96 hr postinfusion (range: 72-120 hr)) was performed for all patients receiving 131 I-MIBG therapy. Post-therapy scans were reviewed by a nuclear medicine radiologist at the University of California, San Francisco for thyroid visualization.
131 I-MIBG uptake in the thyroid was semiquantitatively scored using a point scale: 0 = no uptake, 1 = faint uptake, 2 = definite uptake, 3 = intense uptake. For patients who had more than one scan available, the scan with the highest review assessment was used in the analyses.
Evaluation of Thyroid Dysfunction at Baseline and After 131 I-MIBG Therapy
Pre-and post-therapy TSH and T4 (free T4 when available) values were collected from medical records. Any symptomatology and/or use of thyroid hormone replacement therapy were noted. Abnormal thyroid function at baseline or time points after 131 I-MIBG treatment was defined as TSH and/or T4 concentrations outside of the institutional normal ranges or if patients were noted to be receiving thyroid hormone replacement therapy at that time. Toxicity grade was determined based on CTC v3.0. For TSH and T4 lab values that did not have normal ranges, national age and sex-adjusted normal ranges were used. If one of the two thyroid function measures was not available for a particular time point, only the available measure was evaluated for thyroid function. This type of missing data was very limited, and treating missing TSH or T4 values as normal did not significantly influence the results of the analyses.
Evaluation of Liver Dysfunction at Baseline and After 131 I-MIBG Therapy
Liver function tests, including AST, ALT, and total bilirubin, were closely monitored and recorded pre-therapy and then weekly for the first 6 weeks after therapy and repeated at 3-month intervals for 1 year, then every 6 months, or until the patient died or went on to other therapy. Pre-and post-therapy liver functions were collected and hepatic toxicity was compared to the institutional normal ranges and graded using CTC v2.0 or CTC v3.0 per study protocol. If a normal range at a time point was missing for a patient, the normal range from another time point for the same patient was used, considering that the normal ranges were very similar across different time points. If one or two of the three liver function measures were not available for a particular time point, only the available measures were evaluated for liver toxicity. This type of missing data was limited, and treating missing lab values as normal did not significantly influence the results of the analyses.
Statistical Methods
The cumulative incidence function over time was estimated for both thyroid and liver toxicities [29] . In the analysis of the thyroid data, we evaluated (a) the onset or worsening of thyroid toxicity to Grade 2 (the highest grade of thyroid toxicity in our data) after 131 I-MIBG therapy and (b) the onset or worsening of thyroid toxicity to any grade (Grade 1 or 2) after 131 I-MIBG treatment. In (a), a change from baseline Grade 0 or 1 to Grade 2 thyroid toxicity post-131 I-MIBG therapy was considered an event. In (b), a change from baseline Grade 0 to Grade 1 or 2 after 131 I-MIBG treatment, or a change from baseline Grade 1 to Grade 2 after 131 I-MIBG treatment was considered an event. Patients who did not experience events defined above were censored at the time of the last test date. Patients with Grade 2 thyroid abnormality at baseline were excluded from the cumulative incidence analysis because medical management of thyroid abnormality made it unlikely for these patients to experience a further worsening of thyroid function after 131 I-MIBG treatment. Similarly, in the analysis of the liver data, we evaluated (a) the onset or worsening of liver toxicity to Grade 3 and 4 after 131 I-MIBG treatment and (b) the onset or worsening of liver toxicity to any grade (Grade 1, 2, 3, or 4). In (a), a change from baseline Grade 0, 1, or 2 liver abnormality to Grade 3 or 4 after 131 I-MIBG therapy was considered an event, and in (b), a change from baseline Grade 0 to Grade ≥1, or a change from baseline Grade 1 to Grade ≥2, or a change from baseline Grade 2 to Grade ≥3 was considered an event. Patients who did not experience an event defined above were censored at the time of the last test date. The "time 0" reference for all cumulative incidence analysis was the date of the first 131 I-MIBG treatment.
Analysis of toxicity cumulative incidence and its dependence on patient and disease characteristics was based on the log-rank test, product-limit (Kaplan-Meier) estimator, and univariate and multivariate Cox regression analysis [30] . The cumulative dose of 131 I-MIBG/kg was included as a time-dependent covariate in the Cox regression analysis. Missing data for variables used in multivariate analysis were included in the models as a "missing" category. All Pvalues are two-sided. Estimates of hazard ratio are presented with 95% confidence intervals. Statistical computation was performed using Stata 9.2 [31] .
RESULTS
Analysis Cohort
A total of 194 patients were reviewed for thyroid and liver function. Of these patients, 160 had documented thyroid function values before and after 131 I-MIBG therapy and were evaluable for thyroid toxicity, and 136 had documented liver function values before and after 131 I-MIBG therapy and were evaluable for liver toxicity (Table  I ). Thyroid and liver data were both available in 102 patients. Table I , patient characteristics, shows that this was a heavily pre-treated group of patients, and that approximately 25% of them had more than one 131 I-MIBG therapy. The median cumulative 131 I-MIBG dose was 18.2 mCi/kg (range: 5.0, 54.2). The median time to the last follow-up thyroid function test was 3.5 months, but 36 patients had follow-up thyroid function test results that were obtained 12 months or more after 131 I-MIBG therapy. Thirty-eight (24%) patients presented with abnormal thyroid function values at baseline, including one patient with an X-linked TBG deficiency that pre-disposed him to hypothyroidism, and seven patients who were on L-thyroxine prior to receiving 131 I-MIBG therapy. Among the 136 patients evaluable for liver toxicity, the distribution of age, sex, the number of prior regimens, and cumulative 131 I-MIBG dose was very similar to that with thyroid data (Table I) . Thirty-eight (28%) patients showed baseline liver function abnormality.
Thyroid Abnormalities Following 131 I-MIBG Therapy
Of the 160 patients evaluable for thyroid function following 131 I-MIBG therapy, 7 patients had Grade 2 thyroid toxicity at baseline and remained Grade 2 after 131 I-MIBG treatment. Thirty-one had Grade 1 abnormalities at baseline, and of these, 6 progressed to Grade 2 hypothyroidism, and 14 normalized without intervention. Of the 122 patients with normal baseline thyroid function, 3 developed Grade 2 hypothyroidism and 1 patient developed Grave's disease and had subsequent thyroidectomy. In all, 36 patients experienced an onset or worsening of thyroid function tests after 131 I-MIBG therapy, including 9 who developed Grade 2 hypothyroidism requiring treatment with L-thyroxine (Fig. 1) . Table II and Figure 2A summarize cumulative incidence of onset or worsening of thyroid toxicities after 131 I-MIBG therapy and its relationship with other factors. The seven patients who had Grade 2 thyroid function abnormality at baseline were excluded from the cumulative incidence analysis. In the remaining patients, 15 ± 5% experienced onset of or worsening to Grade 2 hypothyroidism or hyperthyroidism by 2 years after 131 I-MIBG treatment, and 40 ± 7% of patients experienced onset or worsening of any grade ( Fig. 2A) . In univariate and multivariate Cox regression analyses, the risk of Grade 2 toxicity was significantly higher in patients with baseline Grade 1 thyroid abnormality compared to those with normal baseline thyroid function (Table II) . The 2-year cumulative incidence rates in these two groups were 35 ± 14% and 10 ± 5%, respectively. In the analyses of onset or worsening of any grade thyroid toxicity, there was no significant association with baseline thyroid function. Age, sex, the number of previous chemotherapy and biotherapy regimens, thyroid uptake, and cumulative 131 I-MIBG dose did not have a significant impact on thyroid toxicity. Analysis of the cumulative incidence of hypothyroidism alone after 131 I-MIBG therapy showed that at 2 years after treatment, 32 ± 6% of patients experienced an onset or worsening of any grade hypothyroidism, and 12 ± 4% had experienced onset of or worsening to Grade 2 hypothyroidism.
Liver Function Following 131 I-MIBG Therapy
Out of the 136 patients with documented liver function values following 131 I-MIBG therapy, 98 had normal liver function at baseline, of whom 20 remained normal after 131 I-MIBG therapy, 14 experienced Grade 3 or 4 hepatic toxicities, and 64 experienced Grade 1 or 2 toxicity after treatment. Thirty-eight patients had Grade 1 or 2 liver toxicity at baseline, of whom 7 worsened to Grade 3 or 4 after 131 I-MIBG therapy, 7 worsened from Grade 1 to Grade 2, 17 remained the same grade, 1 decreased from Grade 2 to Grade 1, and 6 normalized without intervention. No patient had Grade 3 or 4 liver abnormalities at baseline. Of the 136 patients, a total of 18 patients experienced Grade 3 elevation of at least one measure, and a total of 3 patients experienced Grade 4 elevations (Table III) .
At 2 years post-131 I-MIBG therapy, 76 ± 4% patients had experienced onset or worsening of hepatic toxicities to any grade (Grade Pediatr Blood Cancer DOI 10.1002/pbc Fig. 1 . Flowchart of all patients with pre-and post-therapy thyroid data. 1 Two patients had elevated T4 only, and one patient had both elevated T4 and low TSH. 2 This patient had Grade 1 low TSH only at baseline, but devloped Grade 1 hypothyroidism after 131 I-MIBG treatment. 3 One pateint had elevated T4 only and one patient had both elevated T4 and low TSH. 4 Of these patients, nine developed compensated hypothyroidism. 5 Of these patients, three developed compensated hypothyroidism.
1, 2, 3, or 4) (Fig. 2B) . Most of these toxicities were of Grade 1 or 2. 23 ± 5% of patients had experienced onset of or worsening to Grade 3 and 4 liver toxicity (Fig. 2B) . Table IV summarizes the relationship between cumulative incidence of onset or worsening of liver toxicities after 131 I-MIBG treatment and the other factors among patients reviewed for liver function. In Cox regression analysis, there was no significant association between baseline liver function and the risk of Grade 3 or 4 liver toxicity (Table IV) . However, there was a significant association between baseline liver functioning and onset or worsening of any grade liver toxicity. Patients with abnormal liver function at baseline had a significantly lower risk of progressing to a higher grade toxicity than patients with normal liver function at baseline (P < 0.0001 in both the univariate and multivariate analyses; Table IV) . By 2 years after 131 I-MIBG treatment, 84 ± 4% of patients with normal liver function at baseline and 48 ± 10% of patients with abnormal liver function at baseline had progressed to higher grade toxicity. The above results indicated that the risk of worsening to Grade 3 or 4 liver toxicity post-131 I-MIBG treatment was similar between patients with normal (Grade 0) or abnormal (Grade 1 or 2) baseline liver function, but the risk of worsening into Grade 1 or 2 after 131 I-MIBG treatment for patients who were normal at baseline was higher than the risk of worsening into Grade 2 for patients who had Grade 1 liver abnormality at baseline. Age, gender, and the number of previous chemotherapy or biotherapy regimens were not significantly associated with onset of or worsening to Grade 3 and 4 or onset or worsening of any grade hepatic toxicity. However, cumulative 131 I-MIBG dose showed a trend to be associated with onset or worsening of liver toxicities of any grade (P = 0.079 in the univariate analysis and was significantly associated (P = 0.027) in the multivariate analysis), but it was not associated with incidence of Grade 3 and 4 hepatic toxicity.
Of the 21 patients who had Grade 3 or 4 hepatic toxicities after 131 I-MIBG therapy, only 8 were considered to be possibly related to the 131 I-MIBG therapy; the remainder were coded as "unlikely." For these eight patients, the median follow-up time to the date of first abnormality was 1 month (range: 0.5-9 months). All abnormal values returned to normal after a median time of 15 days (Table III ). The Grade 3 or 4 toxicities for the remaining 13 patients were deemed to be unlikely related to the 131 I-MIBG therapy (Table III) . The recorded abnormal post-therapy values for those 13 patients occurred at a median time of 6 months (range: 2-44 months) after 131 I-MIBG therapy. The factors that probably contributed towards the occurrence of the Grade 3 or 4 liver toxicities among those 13 patients included: other subsequent therapy for neuroblastoma (N = 4), active infections (N = 2), progressive disease (N = 3), or progressive disease and other therapy (N = 4). Other therapies included hu14.18-IL2, myeloablative chemotherapy in preparation for hematopoietic cell transplant, and 13-cis-retinoic acid [32] .
DISCUSSION
This large follow-up study including 194 patients after 131 I-MIBG therapy shows that with proper preventive therapy, damage to the thyroid gland is uncommon and rarely clinically significant. Permanent serious damage to the liver was not evident; most changes were reversible and not clinically significant. In our study, the onset of symptomatic (Grade 2) hypothyroidism at 2 years post-therapy was only 12 ± 4%, while worsening of thyroid function of any degree occurred in 40 ± 7% of children by 2 years after 131 I-MIBG therapy. Elevations of liver function tests were more common, with elevations to Grade 3 or 4 seen in 23 ± 5% of patients by 2 years. The liver toxicity, however, was significantly confounded by other contributing conditions, including other therapies, infections, and disease progression. Out of the 136 patients evaluated for liver toxicity, only 8 had early 131 I-MIBG-related Grade 3 and/or Grade 4 hepatic toxicity, without other concomitant conditions, almost always transient.
TABLE II. Cox Proportional Hazards Model of Cumulative Incidence of Onset or Worsening of Thyroid Toxicity From the Start of
Due to some dissociation of 131 I-MIBG, free iodide contamination of the product, and the biologic degradation of 131 I-MIBG by the liver, free radioiodide is released and may be taken up by the thyroid gland, leading to radiation damage [21, 33] . In order to prevent damage to the thyroid, stable, non-radioactive iodide ion such as potassium iodide is administered to patients prior to 131 I-MIBG therapy to pre-saturate the thyroid. However, based on a study by Picco et al. [22] , primary hypothyroidism occurred in 12/14 patients after 131 I-MIBG therapy, typically within 6-12 months of administration, despite using potassium iodide as a thyroid blocking agent. In another study of 10 patients conducted by Brans et al. [23] , 40% of patients developed hypothyroidism after a mean follow-up time of 11 months, indicating that potassium iodide administration alone was inadequate to protect the thyroid. H.M. van Santen et al. similarly concluded in a separate study that using potassium iodide only for radiation protection of the thyroid gland during 131 I-MIBG treatment in children was less effective than expected. In van Santen's study, up to 64% of 42 children with neuroblastoma treated with 131 I-MIBG (median three therapies) developed TSH elevation, indicating thyroid dysfunction, after an average of 2.3 years [21] .
To decrease hypothyroidism in patients who receive 131 I-MIBG therapy, van Santen conducted another study using a combination of thyroxine, methimazole, and potassium iodide for thyroid protection and demonstrated that this combination appeared more effective than using potassium iodide alone. With the combination of thyroxine, methimazole, and potassium iodide, the hypothyroidism rate in 23 patients with median follow-up of 19 months dropped to 14% thyroid dysfunction following 131 I-MIBG therapy [20] . Using CTC v.3 criteria, the results of our study revealed a 40 ± 7% cumulative incidence rate of onset or worsening of thyroid toxicity of any grade at 2 years after 131 I-MIBG therapy in the patients who used a thyroid protection regimen of both potassium iodide and potassium perchlorate. The cumulative incidence rate of onset of or worsening to symptomatic hypothyroidism alone was 12 ± 4%. Using thyroid toxicity evaluation criteria similar to that of Picco and van Santen who both used elevated TSH to determine thyroid toxicity in their studies, our study showed 12 out of 122 patients with normal baseline thyroid function presented with Grade 1 compensated hypothyroidism after 131 I-MIBG therapy, and 3 out of 122 patients required hormone replacement therapy after treatment, including 1 patient with a family history of hypothyroidism.
The most significant difference between prior studies and the current study was the thyroid blocking regimen used before and after 131 I-MIBG treatment. Rather than using potassium iodide alone or in combination with thyroxine and methimazole, prolonged 6 weeks of administration of potassium iodide was used with 5 days of potassium perchlorate in all six clinical trials reviewed for this study. Based on the decreased incidence of symptomatic hypothyroidism observed in this study, the combination of potassium iodide and potassium perchlorate appears to be more effective than most of the previously used regimens in protecting the thyroid from 131 I-MIBG therapy. However, even with the use of potassium iodide and potassium perchlorate, 29% of patients with evaluable immediate post-therapy scans showed definite or strong thyroid uptake, and 19% of patients showed faint thyroid uptake. However, none of the three patients with normal baseline who were treated with Lthyroxine post-therapy had definite or intense thyroid uptake on their post-therapy scans. Cox regression analyses did not reveal significant association between thyroid uptake and the cumulative incidence of onset or worsening of thyroid toxicity (Table II) . This is consistent with van Santen, who also reported no correlation between thyroid dysfunction and thyroid visualization after 131 I-MIBG administration. In addition to the thyroid blocking regimen, the lower rate of hypothyroidism reported in this study may also be attributed to a shorter median time from 131 I-MIBG therapy to thyroid function follow-up, and a lower median number of therapies. While other studies report the appearance of thyroid dysfunction half a year or more after 131 I-MIBG treatment, the median time to follow-up for this study was 3.5 months. However, 36 patients in this study were followed for more than 1 year. In addition, in only two of the patients who developed asymptomatic elevation of TSH did this occur more than 1 year post-therapy; for the three patients with both elevated TSH and low T4, including two who required hormone therapy, the abnormality developed <6 months after 131 I-MIBG treatment. Because the patient population consisted of refractory or relapsed neuroblastoma patients, many patients either moved on to another therapy shortly after 131 I-MIBG treatment or died, which limited the amount of long-term endocrine data collected and available for analysis.
TABLE III. Summary of Grade 3 and 4 Liver Toxicities Post-
A number of patients (n = 38; 24%) presented with abnormal thyroid function at baseline. This baseline abnormality may again have had to do with the study population, which included a majority of patients who had already been heavily pre-treated prior to 131 I-MIBG therapy. Non-thyroidal illnesses that cause transient disruption in thyroid function may have also played a role in some of the aberrant thyroid functions collected at baseline and may have contributed to some of the thyroid function abnormalities seen after 131 I-MIBG therapy [34] . Family history and the effects of prior therapy, as well as other treatments received after 131 I-MIBG therapy, such as IL-2 or neck irradiation, also may have been contributory factors to thyroid function abnormalities.
Overall, the prophylactic regimen of potassium iodide and potassium perchlorate with 131 I-MIBG therapy is an effective method of protecting the thyroid, resulting in a low incidence rate of clinically significant hypothyroidism. Long-term multi-year follow-up of patients receiving 131 I-MIBG will be necessary as this therapy is moved to front-line to determine if thyroid cancer, as yet unreported, is also a risk, as this is a known late consequence of radiation therapy to the neck or whole body [35, 36] .
The liver is also a target organ for 131 I-MIBG concentration [37] . Uptake within the organ has been consistently shown on conjugate planar imaging and one-third of injected 131 I-MIBG is found within the liver following diagnostic and therapeutic doses.
131 I-MIBG is uniformly taken up by the liver, reaching maximum uptake within 15 min after an intravenous injection of 131 I-MIBG, and is rapidly eliminated. Therefore, hepatic toxicity following 131 I-MIBG therapy has been closely monitored in neuroblastoma patients. Although symptomatic hepatic toxicity has not been reported in patients receiving single agent 131 I-MIBG dosing <12 mCi/kg, there is less information on the effect of 131 I-MIBG exposure to the liver for patients receiving ≥12 mCi/kg of 131 I-MIBG [32, 38, 39] . A recent dosimetry study supports the lack of toxicity seen in our study, as it showed that giving 18 mCi/kg of 131 I-MIBG results in <30 Gy of radiation to the liver, below liver toxicity range [39] .
Liver function abnormalities following 131 I-MIBG therapy were more prevalent than thyroid function abnormalities, with 76 ± 4% of patients experiencing onset or worsening of hepatic toxicity of any grade. Of these patients, only 23 ± 5% experienced Grade 3 and/or 4 liver function abnormalities by 2 years after 131 I-MIBG therapy. However, 13 of 21 cases with onset or worsening of Grade 3 and/or 4 liver toxicity were deemed unlikely related to 131 I-MIBG therapy and attributed to another etiology. Therefore, <10% of patients with evaluable post-therapy liver data had Grade 3 and/or 4 liver toxicity that was possibly attributed to their 131 I-MIBG therapy. Patients with Grade 3 and 4 liver toxicity who did not die shortly after due to progressive disease had their normalization of liver function after a median of 15 days. There were no cases of longterm hepatic complications related to liver function elevation after 131 I-MIBG therapy. Grade 1 and 2 liver toxicities attributable to 131 I-MIBG therapy were transient in patients with extended follow-up information and resolved without intervention.
Although age, gender, and the number of prior cancer treatments were not significantly associated with worsening of hepatic function, a strong correlation was seen between patient baseline liver function and the onset or worsening of any grade liver toxicity. In our analysis, the relative risk of onset of or worsening to Grade 3 or 4 hepatic toxicity after 131 I-MIBG therapy showed a non-significant but positive association with baseline grade, but the relative risk of any onset or worsening of hepatic toxicity was significantly and negatively associated with baseline grade. The latter result suggests that worsening of toxicity by 1 grade level is more likely in patients with normal liver function than for patients with Grade 1 or 2 toxicity at baseline. This apparent paradox may be a result of the fact that so many factors may cause mild elevation of transaminase levels, such as antibiotics and other medications or infections.
In conclusion, the prophylactic regimen of potassium iodide and potassium perchlorate with 131 I-MIBG therapy is an effective thyroid blocking regimen, with a relatively low incidence rate of symptomatic hypothyroidism when compared to prior studies. Liver abnormalities following 131 I-MIBG therapy are primarily transient and do not appear to pose a long-term threat to children who receive 131 I-MIBG therapy for neuroblastoma. Therefore, 131 I-MIBG therapy is a promising treatment for children with refractory or relapsed neuroblastoma with a relatively low rate of significant late thyroid or hepatic dysfunction.
